Developing next-gen ADC products that combine antibody targeting with immune cell granzyme killing into a single hybrid molecule.
AbBC Therapies is a biotechnology company pioneering the Targeted Granzyme B Immunotherapy (TGI) platform — engineered to deliver immune-like cyto-toxicity directly to tumor cells. Our mission is to create safer, scalable, and more effective treatments for cancer and immune-related diseases.
Our mission is to transform cancer therapy by developing Granzyme B-based targeted immunotherapies that are more effective, safer, and more accessible than current ADCs and checkpoint inhibitors. We aim to overcome the limitations of existing modalities by combining biologic precision, robust tumor-cell killing, and immune-system engagement—all within a single therapeutic molecule.
Through continued advancement of our TGI platform, AbBC Therapies seeks to deliver curative-intent therapies that achieve:
Through innovation grounded in biology, we are building a pipeline designed to set a new standard in targeted immunotherapy.
The TGI platform fuses a tumor-targeting antibody with a human Granzyme B enzyme. It achieves ADC-level precision without chemical linkers or synthetic toxins, enabling a simpler biologic design that mimics natural immune defense.
Fully biologic construct
Potent, selective tumor killing
Streamlined manufacturing
Our pipeline spans seven programs in oncology and ophthalmology, progressing from discovery to Phase 1 evaluation. Each program leverages the same modular TGI architecture for faster development.
Active Programs
IND-Enabling Stage
Phase 1 Planned
Stay current with AbBC Therapies' latest updates, publications, and perspectives on the evolving field of biologic immunotherapy.
